Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 3 4Phase 1/2 3Phase 1 2Phase NA 1Phase 2/3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 11Thoracic 9Head & Neck 7Dermatologic 7Tumor-Agnostic 5Other solid neoplasm 5Lymphoid 3Gynecologic 2Genitourinary 2Sarcoma 1Other neoplasm 1NET 1Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 2Neoplasms 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × toripalimab × Genitourinary × Clear all
NCT04374877 2025-11-10

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Coherus Oncology, Inc.

Phase 1 Completed
145 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Neoplasms

NCT04773951 2021-08-24

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Unknown
156 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡